跳至主要内容
临床试验/EUCTR2005-002647-35-HU
EUCTR2005-002647-35-HU进行中(未招募)1 期

epafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo (Nepafenac Vehicle) for the Prevention and Treatment of Ocular Inflammation and Ocular Pain Associated with Cataract Surgery. European Study.

Alcon Research, Ltd0 个研究点目标入组 0 人开始时间: 2005年8月18日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Adults (18 years of age or older) of any race, who have a cataract, and are expected to undergo cataract extraction by phacoemulsification with the implantation of a posterior chamber IOL.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Use of topical ocular or systemic steroids within 14 days prior to surgery.
  • Use of topical ocular, inhaled or systemic NSAIDs within 7 days of surgery (exception: low dose aspirin, up to 100mg, permitted).
  • Any intraocular inflammation or more than mild ocular pain at the baseline visit
  • Women of child-bearing potential who are breast-feeding, have a positive urine pregnancy test at baseline, or not using adequate birth control.
  • History of chronic or recurrent inflammatory eye disease in the operative eye.
  • Proliferative diabetic retinopathy or moderate to severe non-proliferative diabetic retinopathy in the operative eye; or uncontrolled diabetes mellitus.
  • Known or suspected allergy or hypersensitivity to NSAIDs, or any component of the study medication.

研究者

发起方
Alcon Research, Ltd

相似试验

进行中(未招募)
1 期
epafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo (Nepafenac Vehicle) for the Prevention and Treatment of Ocular Inflammation and Ocular Pain Associated with Cataract Surgery. European Study.ocular pain and inflammation associated with cataract extraction and intraocular lens implantation
EUCTR2005-002647-35-GBAlcon Research, Ltd
进行中(未招募)
1 期
epafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution & Placebo (Nepafenac Vehicle) for the Prevention & Treatment of Ocular Inflammation & Ocular Pain Associated with Cataract Surgery. European Study.Nepafenaco 0,1% colirio suspensión comparado con Ketorolaco trometamol 0,5% colirio solución y placebo (vehículo de Nepafenaco) en prevención y tratamiento de la inflamación ocular y del dolor ocular asociados a la cirugía de catarata: Estudio Europeo. - nepafenac ophthalmic Eocular pain and inflammation associated with cataract extraction and intraocular lens implantation
EUCTR2005-002647-35-ESAlcon Research, Ltd225
进行中(未招募)
不适用
epafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo (Nepafenac Vehicle) for the Prevention and Treatment of Ocular Inflammation and Ocular Pain Associated with Cataract Surgery. European Study. - Nepafenac Ophthalmic Eocular pain and inflammation associated with cataract extraction and intraocular lens implantation
EUCTR2005-002647-35-PTAlcon Research, Ltd225
进行中(未招募)
不适用
epafenac 0.1 Eye Drops, Suspension compared to Ketorolac Trometamol 0.5 Eye Drops, Solution and Placebo Nepafenac Vehicle for the Prevention and Treatment of Ocular Inflammation and Ocular pain associated with Cataract Surgery European Study.non steroidal anti inflammatory drug for prophylaxix and teraphy of ocular inflammation and ocular pain after cataract surgery.MedDRA version: 6.1Level: PTClassification code 10015943
EUCTR2005-002647-35-ITALCON ITALIA
招募中
4 期
A study comparing efficacy of two drops in patients undergoing a laser for closed angles
CTRI/2018/10/016227Aravind Eye Hospital